SCHEMBL4417488

SCHEMBL4417488

Cn1cccc1CN1CC2C(CNc3ccc(N4CCOCC4)c(F)c3)C2C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.41
NPC1 O15118 5/20 0.39
RAB9A P51151 4/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 1/20 0.38
GAA P10253 3/20 0.37
ALOX15 P16050 3/20 0.37
MAPK1 P28482 2/20 0.37
USP30 Q70CQ3 1/20 0.37
HTT P42858 2/20 0.37
MAOB P27338 3/20 0.37
LMNA P02545 2/20 0.37
MAOA P21397 1/20 0.37
PTGS1 P23219 1/20 0.37
CALML3 P27482 1/20 0.37
SDHA P31040 1/20 0.37
ALDH1A1 P00352 3/20 0.35
DGAT1 O75907 1/20 0.35
HSD17B10 Q99714 1/20 0.35
MTOR P42345 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4419245 0.84 NPC1 (0.46) L3MBTL1NPC1RAB9AMAPTKMT2A
SCHEMBL2180736 0.82 CYP2A13 (0.46) L3MBTL1NPC1RAB9AMAPTKMT2A
SCHEMBL4412123 0.82 L3MBTL1 (0.41) L3MBTL1NPC1RAB9AMAPTKMT2A
SCHEMBL2170676 0.82 LMNA (0.44) L3MBTL1NPC1RAB9AMAPTKMT2A
SCHEMBL4412370 0.82 L3MBTL1 (0.44) L3MBTL1NPC1RAB9AMAPTKMT2A
SCHEMBL4413699 0.82 GAA (0.48) L3MBTL1NPC1RAB9AMAPTKMT2A
SCHEMBL4424484 0.81 LMNA (0.41) L3MBTL1NPC1RAB9AMAPTKMT2A
SCHEMBL4425789 0.81 NPC1 (0.51) L3MBTL1NPC1RAB9AMAPTKMT2A
SCHEMBL4552124 0.81 P2RX3 (0.43) L3MBTL1NPC1RAB9AMAPTKMT2A
SCHEMBL4422515 0.80 L3MBTL1 (0.40) L3MBTL1NPC1RAB9AMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 L3MBTL1 1416/4885NPC1 301/4885RAB9A 816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.